Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + amoxicillin dual therapy for refractory Helicobacter pylori infection
ChiCTR2200055125Phase 4Recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vonoprazan and amoxicillin in Helicobacter pylori infection, sponsored by Changzhou Second People's Hospital. Primary endpoint: Eradication rate. Started Jan 2022; status: recruiting.
02
Drugs
vonoprazanamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2200055125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055125.